{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2005"],"condition":["Colorectal Neoplasms","Neoplasms"],"disease":["Colorectal Neoplasms","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2049493"],"location":["United States"],"study_start_month":["9"],"keyword":["Sunitinib","Oxaliplatin","Colorectal cancer,","Advanced solid tumors,","Sunitinib (SUTENT),","Leucovorin","FOLFOX","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors","description":"This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin]. Three different dosing regimens with starting doses of sunitinib at 37.5 mg/day (Schedule 2/2, Schedule 4/2, and Continuous Dosing) were tested in patients with advanced solid tumors, including colorectal cancer.","dates":{"creation":"2005-09-15"},"accession":"2049493","cross_references":{"ClinicalTrials___gov":["NCT00599924"]}}